- Home
- ACRS vs FRST Comparison
ACRS vs FRST Comparison
Compare ACRS & FRST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ACRS | FRST |
|---|---|---|
| Founded | 2012 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 230.8M | 261.7M |
| IPO Year | 2015 | 2006 |
Fundamental Metrics
Financial Performance| Metric | ACRS | FRST |
|---|---|---|
| Price | $3.06 | $13.38 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $9.75 | N/A |
| AVG Volume (30 Days) | ★ 1.2M | 89.0K |
| Earning Date | 11-06-2025 | 01-27-2026 |
| Dividend Yield | N/A | ★ 3.01% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.34 |
| Revenue | $15,742,000.00 | ★ $138,816,000.00 |
| Revenue This Year | N/A | $13.75 |
| Revenue Next Year | $6.06 | $35.05 |
| P/E Ratio | ★ N/A | $39.11 |
| Revenue Growth | N/A | ★ 33.08 |
| 52 Week Low | $1.05 | $7.59 |
| 52 Week High | $3.48 | $13.53 |
Technical Indicators
Market Signals| Indicator | ACRS | FRST |
|---|---|---|
| Relative Strength Index (RSI) | 56.89 | 77.92 |
| Support Level | $3.12 | $13.23 |
| Resistance Level | $3.48 | $13.53 |
| Average True Range (ATR) | 0.22 | 0.33 |
| MACD | -0.00 | 0.17 |
| Stochastic Oscillator | 52.54 | 92.06 |
Price Performance
Historical ComparisonAbout ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.
About FRST Primis Financial Corp.
Primis Financial Corp is the bank holding company for Primis Bank, providing financial services to individuals and small and medium-sized businesses. Primis Bank offers a wide range of commercial banking services, It focuses on making loans secured mainly by commercial real estate and other types of secured and unsecured commercial loans to small and medium-sized businesses in several industries, as well as loans to individuals for a variety of purposes. Primis Bank offers a broad range of deposit products, including checking (NOW), savings, money market accounts, and certificates of deposit. Its operating segments are Primis Mortgage, Primis Bank, and Other.